Lately the biotech/gene and therapeutics issues have been all trading up on above average volume as money rotates into the group for the first time in a while. This area looks to be establishing itself as an emerging leadership area. Today two new issues, ILMN and NABI pop up on the FusionIQ Short Squeeze screen. Both have sizeable float adjusted short interests (24 % and 11 % respectively) and higher point and figure price targets ($ 111 and $ 8.75 respectively).
Given the rotation to biotech these two names look to offer solid near-term return potential.